Concord Drugs Limited
Concord Drugs Limited Fundamental Analysis
Concord Drugs Limited (CONCORD.BO) shows weak financial fundamentals with a PE ratio of 131.90, profit margin of 1.28%, and ROE of 1.69%. The company generates $0.4B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 31.8/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze CONCORD.BO's fundamental strength across five key dimensions:
Efficiency Score
WeakCONCORD.BO struggles to generate sufficient returns from assets.
Valuation Score
WeakCONCORD.BO trades at a premium to fair value.
Growth Score
ModerateCONCORD.BO shows steady but slowing expansion.
Financial Health Score
ExcellentCONCORD.BO maintains a strong and stable balance sheet.
Profitability Score
WeakCONCORD.BO struggles to sustain strong margins.
Key Financial Metrics
Is CONCORD.BO Expensive or Cheap?
P/E Ratio
CONCORD.BO trades at 131.90 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, CONCORD.BO's PEG of 3.78 indicates potential overvaluation.
Price to Book
The market values Concord Drugs Limited at 2.21 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 12.66 times EBITDA. This signals the market has high growth expectations.
How Well Does CONCORD.BO Make Money?
Net Profit Margin
For every $100 in sales, Concord Drugs Limited keeps $1.28 as profit after all expenses.
Operating Margin
Core operations generate 6.85 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $1.69 in profit for every $100 of shareholder equity.
ROA
Concord Drugs Limited generates $0.84 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Concord Drugs Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Concord Drugs Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
CONCORD.BO converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
131.90
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
3.78
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.21
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.66
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.50
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.55
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.02
vs 25 benchmark
ROA
Return on assets percentage
0.008
vs 25 benchmark
ROCE
Return on capital employed
0.08
vs 25 benchmark
How CONCORD.BO Stacks Against Its Sector Peers
| Metric | CONCORD.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 131.90 | 29.45 | Worse (Expensive) |
| ROE | 1.69% | 779.00% | Weak |
| Net Margin | 1.28% | -24936.00% (disorted) | Weak |
| Debt/Equity | 0.50 | 0.26 | Weak (High Leverage) |
| Current Ratio | 1.55 | 4.65 | Neutral |
| ROA | 0.84% | -19344.00% (disorted) | Weak |
CONCORD.BO outperforms its industry in 0 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Concord Drugs Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation